Moderna, Inc. (MRNA), headquartered in Cambridge, Massachusetts, is a leading biotechnology company committed to pioneering ...

The US Department of Health and Human Services awarded Moderna $590 million to continue developing a vaccine to protect against bird flu.

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

Moderna wins EU tender to supply COVID-19 vaccines for up to four years, offering diverse formats like prefilled syringes to ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

The money will go to Moderna, the Massachusetts-based pharmaceutical company that previously developed a COVID-19 vaccine.

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Hold rating on Moderna (MRNA – Research Report), with a price ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled ...

Jan 17 (Reuters) - The U.S. government has awarded Moderna (MRNA.O), opens new tab $590 million to advance the development of its bird flu vaccine, as the country doubles down on efforts to tackle ...

Moderna is a stock that deserves a closer look. The company still has several fundamental strong points, including an extensive pipeline of therapeutics in clinical trials that could be the ...